What's coming: CAR-T & the immune reset

The headline: CAR-T cell therapy — the technology that revolutionised some cancers — is being turned on autoimmune disease. It deeply wipes out the misbehaving B cells and lets the immune system 'reboot.' In early autoimmune patients (lupus first, now expanding to RA) it has produced years of drug-free remission with the disease antibodies erased — a single treatment acting less like control and more like a reset. The essential caveats: it's very early in RA (tiny numbers, short follow-up, severe/refractory cases), it needs chemotherapy to prepare, it carries real risks, and it's hugely expensive. Not mainstream today — but genuinely unprecedented. Evidence ●●○○○ in RA

Instead of suppressing the whole immune system, 'inverse vaccines' and tolerogenic cell therapies aim to switch off only the RA-specific response — teaching the immune system to tolerate its own citrullinated proteins again. Early trials (DEN-181, tolerogenic dendritic cells) are safe and mechanistically encouraging; the dream is durable tolerance with no chronic immunosuppression. Early — but the direction many believe is the real future. Evidence ●●○○○

The near-term drug pipeline is a mix: some novel targets have failed (the GM-CSF inhibitor otilimab flopped in refractory disease — a reminder that not every 'novel target' works), while bispecific antibodies, joint-targeted 'nanomedicine' delivery, and next-generation JAK inhibitors are in earlier development. Progress is real but often incremental — the transformative bets are the reset and tolerance approaches above. Evidence ●●○○○